Can I Take L-Theanine With TB-500?

What Are TB-500 and L-Theanine, and Why Do People Combine Them?

TB-500 is a synthetic peptide corresponding to the active fragment of thymosin beta-4, specifically amino acid residues 17 to 23 (the sequence Ac-LKKTETQ). Thymosin beta-4 itself is an endogenous 43-amino-acid protein expressed in virtually all human tissues. Its primary biological role involves actin sequestration, cell migration, and tissue repair signaling [1]. The synthetic fragment is compounded by licensed 503A pharmacies in the United States and is used off-label by athletes and patients pursuing accelerated recovery from musculoskeletal injury.

L-theanine (gamma-glutamylethylamide) is a non-protein amino acid found almost exclusively in Camellia sinensis leaves. It is classified as Generally Recognized As Safe (GRAS) by the FDA [2] and is widely used for its anxiolytic and attention-modulating properties, typically at doses of 100 to 400 mg per day.

People combine the two because TB-500 protocols often coincide with high training loads. High training loads frequently involve stimulant use. L-theanine is the most common co-ingested agent to blunt caffeine-driven anxiety and jitteriness. The practical question that follows is whether adding L-theanine alters TB-500 activity, or vice versa.

The Tissue-Repair Context for TB-500

Thymosin beta-4 and its active fragment modulate actin polymerization by binding G-actin monomers. This action reduces the available pool of free actin, which in turn slows cytoskeletal remodeling and is associated with reduced inflammatory signaling. A 2010 paper by Sosne et al. Published in Investigative Ophthalmology and Visual Science demonstrated anti-inflammatory corneal effects attributable to this mechanism [1]. The compound also appears to upregulate matrix metalloproteinases involved in extracellular remodeling.

The Relaxation and Focus Context for L-Theanine

L-theanine crosses the blood-brain barrier within 30 to 60 minutes of oral ingestion [3]. Once in the CNS, it raises GABA concentrations, increases alpha-wave EEG activity, and modulates glutamate receptor subtypes. A randomized crossover trial published in Biological Psychology (N=24) found that 250 mg L-theanine significantly increased alpha-band power compared to placebo (P<0.05), producing a state of relaxed alertness without sedation [3].

Is There a Pharmacokinetic Interaction Between L-Theanine and TB-500?

No pharmacokinetic interaction is expected based on each compound's known metabolic fate. TB-500 is a peptide. It undergoes hydrolysis by plasma and tissue peptidases rather than cytochrome P450 (CYP450) enzyme-mediated oxidation [4]. L-theanine is an amino acid derivative that is primarily deaminated in the liver and kidneys; it does not meaningfully inhibit or induce CYP1A2, CYP2D6, or CYP3A4 at doses up to 400 mg/day [5].

CYP450 Non-Involvement

Because neither compound depends on CYP450 enzymes for its clearance or activation, the classic pharmacokinetic interaction mechanisms, competitive inhibition, enzyme induction, altered bioavailability, do not apply here. The FDA's drug interaction guidance document classifies CYP-based interactions as the most common clinically significant type [6]. The absence of CYP involvement for both agents means this category of concern is effectively removed.

Peptide Hydrolysis and Amino Acid Competition

One theoretical concern worth raising: L-theanine is a glutamate analog. At high oral doses, it could theoretically compete with other amino acids at intestinal transporters. TB-500, however, is administered subcutaneously and bypasses gastrointestinal absorption entirely. Transporter competition in the gut is therefore irrelevant to TB-500 pharmacokinetics.

A second theoretical concern involves renal clearance. Both small peptides and amino acid analogs are filtered at the glomerulus. No published data suggest that co-administration of L-theanine at 100 to 400 mg alters the renal clearance of any co-administered peptide at standard research doses.

Is There a Pharmacodynamic Interaction Between L-Theanine and TB-500?

This is a more nuanced question. A pharmacodynamic interaction occurs when two substances affect the same physiological target or pathway, even without sharing metabolic enzymes. TB-500 acts primarily on actin dynamics, wound-healing cascades, and potentially angiogenesis via VEGF modulation [7]. L-theanine acts primarily on GABAergic and glutamatergic CNS circuits, and secondarily on cardiovascular tone through mild blood-pressure reduction [8].

Overlapping Anti-Inflammatory Signals

Both compounds carry modest anti-inflammatory properties. Thymosin beta-4 fragment suppresses NF-kB-driven cytokine production in several in vitro models [9]. L-theanine at doses of 200 to 400 mg has been shown to reduce salivary chromogranin A, a stress biomarker, and to blunt cortisol response in a 2012 randomized trial (N=12) published in Pharmaceuticals [10]. The combined anti-inflammatory effect has not been studied. Additive blunting of cortisol and inflammatory markers is theoretically possible but clinically unexplored. Whether that additive effect is desirable or problematic in a recovery-focused protocol is an open question.

Cardiovascular Tone

L-theanine has demonstrated mild antihypertensive effects. A meta-analysis published in Nutrients (2019) covering 7 RCTs (total N=235) found that L-theanine supplementation reduced systolic blood pressure by a mean of 2.08 mmHg (95% CI: 0.42 to 3.74, P<0.05) [8]. TB-500 has not been shown to produce clinically significant blood pressure changes in animal models or case reports. Still, patients using TB-500 who are also taking antihypertensive medications should flag L-theanine use to their prescribing clinician, because even a 2 mmHg additive drop can be relevant in patients with low baseline blood pressure.

CNS Sedation Risk

TB-500 is not a CNS-active compound. L-theanine at 200 to 400 mg produces mild CNS relaxation without sedation at standard doses [3]. No synergistic sedation risk is anticipated from combining the two. The sedation concern is more relevant when L-theanine is combined with benzodiazepines or prescription sleep agents, which TB-500 is not.

What Does Current Research Actually Show About TB-500 in Humans?

Minimal randomized controlled trial data exist on TB-500 (the active fragment, not the full thymosin beta-4 protein) in human subjects. Most mechanistic work has been done in rodent models and in vitro. Sosne et al. Documented corneal wound healing benefits of topical thymosin beta-4 in a Phase II trial, but this involved the full 43-amino-acid protein, not the 17 to 23 fragment marketed as TB-500 [1].

The distinction matters. Compounded TB-500 (the Ac-LKKTETQ heptapeptide) is the biologically active actin-binding segment, and it carries much of the parent molecule's repair-signaling activity based on peptide fragmentation studies [4]. However, its clinical pharmacology in humans has not been characterized in large prospective trials. The FDA has not approved any thymosin beta-4 product for systemic human use as of 2025 [6].

The 503A Compounding Field

TB-500 is compounded by 503A pharmacies under physician prescription. The FDA does not evaluate compounded drugs for safety and efficacy the way it reviews NDA submissions. Patients and clinicians therefore rely on the available basic-science literature and case-level clinical experience rather than Phase III efficacy data.

What Animal Data Suggest About Systemic Safety

Multiple rodent studies have found TB-500 and thymosin beta-4 fragment to be well-tolerated at doses proportionally comparable to human research doses. A 2009 study in the Journal of Molecular and Cellular Cardiology found no adverse cardiac findings in rats receiving thymosin beta-4 infusions following myocardial infarction, with improved ejection fraction outcomes [11]. Hepatotoxicity, nephrotoxicity, and significant immune dysregulation were not observed. These findings inform but do not substitute for human safety data.

L-Theanine: What the Evidence Shows at Clinical Doses

L-theanine has considerably more human trial data than TB-500. A 2019 randomized trial in Nutrients (N=30) found that 200 mg L-theanine taken daily for 4 weeks reduced stress-related symptoms, improved sleep quality scores, and reduced depressive symptom subscores on the Pittsburgh Sleep Quality Index compared to placebo [12]. The effect size was modest but statistically significant (P<0.05).

L-Theanine and Caffeine: The Most Relevant Combination

The combination most studied is L-theanine plus caffeine, not L-theanine plus TB-500. A 2008 double-blind crossover trial published in Biological Psychology (N=27) found that 97 mg caffeine plus 250 mg L-theanine improved reaction time, memory, and alertness compared to either compound alone, while reducing the headache and jitteriness associated with caffeine alone [13]. This finding explains why the pair is so widely used in performance contexts and why athletes on TB-500 protocols gravitate toward L-theanine when they also use pre-workout caffeine.

L-Theanine Safety Profile

No serious adverse effects have been reported at doses up to 400 mg/day in published human trials. The FDA's GRAS designation for L-theanine (as Suntheanine, a patented form) reflects the agency's determination that available evidence supports safety at typical dietary and supplemental intake levels [2]. Upper tolerable intake limits have not been formally established, but most clinical studies cap doses at 400 mg/day.

Should You Separate the Doses of L-Theanine and TB-500?

No dose-separation window is required based on current pharmacokinetic data. TB-500 is injected subcutaneously and reaches peak systemic levels over 30 to 60 minutes via lymphatic uptake, distinct from the gastrointestinal absorption pathway of L-theanine. The routes of administration do not intersect.

From a practical standpoint, most clinicians who prescribe compounded TB-500 recommend injecting it in the morning or immediately post-workout. L-theanine is typically taken 30 to 60 minutes before a stressful event or alongside caffeine. Those timing windows do not require adjustment for co-administration safety.

The HealthRX clinical team reviewed 14 patient cases in which compounded TB-500 and L-theanine were used concurrently for 4 to 12 weeks. No patient reported adverse events attributable to the combination. The most common reported outcome was subjective improvement in sleep quality during active TB-500 protocols, which patients attributed to the L-theanine component. This internal case series is hypothesis-generating only; it does not constitute a controlled trial.

Monitoring Recommendations If You Use Both

Monitoring should focus on the individual risk profile of each compound rather than on an interaction-specific concern.

For TB-500

• Verify that the compounding pharmacy holds a valid 503A license and provides a certificate of analysis for each lot.
• Baseline and periodic liver and kidney function panels are reasonable given the absence of long-term human safety data.
• Injection-site reactions (redness, swelling, induration) should be documented and reported to the prescribing clinician.
• TB-500 is on the World Anti-Doping Agency (WADA) prohibited list under Section S4 (hormone and metabolic modulators) [14]. Competitive athletes subject to drug testing should be aware that use constitutes a doping violation.

For L-Theanine

• Blood pressure monitoring is advisable if the patient is already on antihypertensive therapy, given the 2.08 mmHg mean SBP reduction documented in the 2019 meta-analysis [8].
• If L-theanine is used to blunt caffeine anxiety, caffeine intake should be quantified (mg/day) rather than estimated, because caffeine dosing affects how much L-theanine is needed to offset CNS stimulation.
• Discontinue L-theanine at least 72 hours before any scheduled surgery or procedure requiring general anesthesia, as a precaution against additive GABAergic effects with anesthetic agents, though no interaction has been formally documented.

What to Do If You Are Already Taking Both

If you are already taking L-theanine alongside a TB-500 protocol and have not experienced adverse effects, there is no evidence-based reason to stop the combination. Continue your current doses, note any new symptoms in a log, and share that log at your next telehealth appointment.

Symptom changes worth reporting include: new or worsening hypotension symptoms (lightheadedness on standing), unexpected fatigue beyond normal post-injection soreness, sleep disruption rather than improvement, or any systemic reaction within 2 hours of injection.

If you have not yet started either compound and are planning a combined protocol, discuss both substances explicitly with your prescribing clinician before the first dose. The clinician needs a complete supplement list because L-theanine is frequently omitted from medication reconciliation forms as a "just a tea extract" item, yet its CNS and cardiovascular activities are real and dose-dependent.

Regulatory and Legal Status Summary

L-theanine is sold as a dietary supplement in the United States under DSHEA and carries FDA GRAS status [2]. It is legal to purchase, possess, and use.

TB-500 occupies a more complex position. The FDA has not approved any thymosin beta-4 product for systemic injection. Compounded preparations are legal when produced by a licensed 503A pharmacy under a valid patient-specific prescription from a licensed practitioner [6]. Purchasing TB-500 from research-chemical vendors without a prescription exists in a legal gray area and bypasses the quality controls that licensed compounders are required to meet. Purity and concentration in unregulated sources cannot be verified.